Consortium hopes to improve childhood cancer survival in Africa
Oxford Nanopore Technologies has joined the PROGRESS study to support improved outcomes for childhood leukaemias in Ghana.
The consortium so far includes Yemaachi Biotech, Pediatric Oncology Units at Korle Bu Teaching Hospital, Komfo Anokye Teaching Hospital and Greater Accra Regional Hospital, and institutions like Newcastle University, UK.
It aims to leverage world-class expertise and technology to address the pressing issue of childhood cancer in Africa, with a view to setting a new standard for future diagnosis and treatment in resource-limited settings.
PROGRESS aims to improve survival rates for childhood cancers in low- and middle-income countries where survival rates can be lower than 30%, compared to over 80% in high-income countries.
The project, funded in part by LifeArc, has the potential to play a pivotal role in contributing towards the World Health Organization’s goal of a 60% survival rate by 2030 for all children with cancer globally.
The “transformative potential” of genomic technology
The study will pilot the use of nanopore sequencing for minimal residual disease (MRD) detection in paediatric acute lymphoblastic leukaemia (ALL) in Ghana.
Gordon Sanghera, CEO of Oxford Nanopore Technologies, commented: “By integrating our cutting-edge sequencing technology into the PROGRESS Study, this is not only enhancing capabilities in resource-limited settings but also paving the way for widespread improvements in childhood cancer treatment across Africa. This partnership exemplifies the transformative potential of genomic technology to deliver real-world impact and improve healthcare outcomes for all.”
This study, initiated by Yemaachi Biotech and the paediatric oncology unit at the Korle Bu Teaching Hospital, is designed as a proof-of-concept for validation and broader adoption across Africa. Yemaachi Biotech’s network of clinical partners, currently spanning nine African countries, will facilitate the project’s expansion.
This will be the first time that sequencing for childhood leukaemias has been done in Ghana. The project will enable clinical research teams to access genomic insights for all patients, significantly increasing understanding of the genetic basis of paediatric leukaemias among African children. To date, more than 100 children have been recruited into the PROGRESS study.
“PROGRESS is a game changer for paediatric oncology in Ghana and potentially the rest of Africa. Through this work with Yemaachi and Oxford Nanopore, we are progressing at pace to incorporate cutting edge technology into clinical care and demonstrating that high quality collaborative research is possible in LMIC,” said Dr Cathy Segbefia, Paediatric Haematologist Oncologist and Principal Investigator of PROGRESS.
Diana Spencer, Senior Digital Content Editor, DDW
